FindTrial
Sign In

Effect of trikatu arka over medohara guggulu in overweight

To evaluate the efficacy of Trikatu arka over Medoharaguggulu in Hinasthoulya with special reference to Over weight

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/031903
Enrollment
40
Registered
2021-03-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E663- Overweight

Interventions

Intervention1: Trikatu arka: dose-15ml frequency- two times a day, route of administration- oral, duration of therapy- one month Control Intervention1: Medoharaguggulu: dose- tablets(500mg each) frequ

Sponsors

Dr Shyni MS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosedand confirmed cases of on the basis of classical symptoms like Alasya, Alpabala, Ayatopachaya, Nidradikya, Kshutatimatram, Pipasatimatram, Kshudraswasam19. 2. Patients of age between 16-50years of either sex. 3. B.M.I 25 TO 30 Kg/m2

Exclusion criteria

Exclusion criteria: 1. Patients with hypertension, diabetes mellitus 2. Patient with evidence of Renal, Hepatic, Cardiac involvement 3. Patient with Hypothyroidism(Endocrinal dysfunctions) 4. Patient on long termed steroid treatment. 5. Pregnant women and lactating women.

Design outcomes

Primary

MeasureTime frame
subjective parameters like Alasya Alpabala Ayatopachaya Nidradikya and objective parameters like weight BMI waist hip ratio will be reducedTimepoint: 45days—

Secondary

MeasureTime frame
reduction in the objective criteria - weight and BMI reduction and subjective criteria - Alasya Alpabala Ayatopachaya Nidradikya will be reduced Timepoint: 45 days—

Countries

India

Contacts

Public ContactDr Shyni MS

DGM Ayurvedic Medical College

yasmeenphaniband@gmail.com9845515865

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026